| Name of the Instrument/Tool | Sjögren’s Tool for Assessing Response (STAR) |
| First Description |
Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, et al. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Ann Rheum Dis. 2022 Jul;81(7):979-989. doi: 10.1136/annrheumdis-2021-222054. Epub 2022 Apr 7. PMID: 35393271; PMCID: PMC9209686. |
| Year | 2022 |
| Domains | |
| Concept of constructs | Disease activity |
| Population/Disease | Disease specific |
| Originally developed for | Sjögren's syndrome |
| Other rheumatic diseases where can be applied (only if validated) |
--- |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English |
| Available in Language | --- |
| REFERENCE IDENTIFICATION | |
| Author/s | Seror R, Baron G, Camus M, Cornec D, Perrodeau E, Bowman SJ, Bombardieri M, Bootsma H, Gottenberg JE, Fisher B, Hueber W, van Roon JA, Devauchelle-Pensec V, Gergely P, Mariette X, Porcher R; NECESSITY WP5 - STAR development working group; NECESSITY WP5- STAR development working group. |
| Title | Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. |
| Journal | Ann Rheum Dis |
| Year | 2022 |
| Vol | 81 |
| Num | 7 |
| Pages | 979-989 |
| Country | Multinaltional |
| Language | English |
| Other references of interest | |
| Link | https://pubmed.ncbi.nlm.nih.gov/19561361/ |
| Brief Description |
Seror R, Ravaud P, Bowman SJ, et al. . EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103–9. 10.1136/ard.2009.110619 - |
| Link | https://pubmed.ncbi.nlm.nih.gov/24411404/ |
| Brief Description |
Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Mariette X, Vitali C. Outcome measures for primary Sjögren's syndrome: a comprehensive review. J Autoimmun. 2014 Jun;51:51-6. doi: 10.1016/j.jaut.2013.12.010. Epub 2014 Jan 8. PMID: 24411404. |
| Link | https://pubmed.ncbi.nlm.nih.gov/27150113/ |
| Brief Description |
Outcome measures used within the STAR : Seror R, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Annals of the Rheumatic Diseases 2011;70:968-72. Hocevar A, et al. Ultrasonographic changes of major salivary glands in primary Sjogren's syndrome. Diagnostic value of a novel scoring system. Rheumatology (Oxford). 2005 Jun;44(6):768-72. doi:10.1093/rheumatology/keh588. Epub 2005 Mar 1. PMID: 15741192. |
| Instrument/Tool Translations References | |
| No other References. | |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Raphaele Seror |
| raphaele.seror@aphp.fr | |
| Address | Paris-Saclay University, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin-Bicetre, France |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Composite Index |
| Brief Description |
Sjögren’s Tool for Assessing Response (STAR) is intended to assess treatment efficacy based on improvement of disease activity in clinical trials of drugs for primary Sjögren’s syndrome (pSS). This composite responder index globally assesses all disease features and for use as an efficacy endpoint in RCTs. The STAR contains 5 domains: systemic activity, symptoms, lacrimal and glandular gland function, and biomarkers of auto-immune activity. The domains are differently weighted. |
| Number of Items | 5 |
| Range | 0-9 |
| Responses options/scale |
Yes Different points for each domain |
| Developed for | Research, Clinical practice |
| PRACTICAL APPLICATION | |
| Method of administration | Physician |
| Recommendations to score |
Items are summed: systemic activity (3 points), symptoms (3 points), lacrimal (1 point) and glandular (1 point) gland function, and biomarkers of auto-immune activity (1 point). |
| Score Interpretation | The higher the score, the higher the disease activity. |
| Cut-off points | ≥ 5-point score corresponds to a clinically relevant difference, and is the definition of reponse to therapy. |
| Cut-off points applied to | --- |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | - minutes |
| Scoring time by the assessor | - minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research, Easy to use |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments | --- |